| pubmed-article:1930940 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1930940 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:1930940 | lifeskim:mentions | umls-concept:C0011849 | lld:lifeskim |
| pubmed-article:1930940 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:1930940 | lifeskim:mentions | umls-concept:C0314657 | lld:lifeskim |
| pubmed-article:1930940 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:1930940 | pubmed:dateCreated | 1991-12-20 | lld:pubmed |
| pubmed-article:1930940 | pubmed:abstractText | The aetiology of insulin-dependent diabetes (IDDM) involves genetic predisposition, a major component of which has been mapped in the HLA complex, near to or identical with genes encoding class II molecules. In Caucasian populations IDDM is strongly associated with the serologically defined HLA-DR3 and DR4 antigens, which are widely recognised as markers of susceptibility. The particularly high risk of DR3/DR4 heterozygotes suggests that susceptibility is determined by two genes acting synergistically. The development of recombinant DNA technology has allowed a finer description of the class II region and provided evidence that DQ rather than DR determinants may primarily influence IDDM susceptibility. The search for specific structural changes of the DQA and DQB genes has shown that susceptibility correlates with the absence of aspartic acid at position 57 on the DQ beta chain (DQ beta 57 Asp--) and/or the presence of arginine at position 52 on the DQ alpha chain (DQ alpha 52 Arg+). In Caucasians the formation of a putative DQ susceptibility molecule (DQ alpha 52 Arg+, DQ beta 57 Asp-) accounts best for the disease associations when transcomplementation molecules consisting of DQ alpha and beta chains encoded by different haplotypes are postulated to explain the excess risk of heterozygotes. The HLA-IDDM associations in the Japanese, however, are not explained by this model. These and other unresolved questions indicate that other residues of the DQ alpha and beta chains or other class II molecules (DR beta chains), as well as non-MHC genes, may also contribute to the susceptibility. | lld:pubmed |
| pubmed-article:1930940 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1930940 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1930940 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1930940 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1930940 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1930940 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1930940 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1930940 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1930940 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1930940 | pubmed:issn | 0785-3890 | lld:pubmed |
| pubmed-article:1930940 | pubmed:author | pubmed-author:HorsJJ | lld:pubmed |
| pubmed-article:1930940 | pubmed:author | pubmed-author:DeschampsII | lld:pubmed |
| pubmed-article:1930940 | pubmed:author | pubmed-author:RobertJ JJJ | lld:pubmed |
| pubmed-article:1930940 | pubmed:author | pubmed-author:KhalilII | lld:pubmed |
| pubmed-article:1930940 | pubmed:author | pubmed-author:BeressiJ PJP | lld:pubmed |
| pubmed-article:1930940 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1930940 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:1930940 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1930940 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1930940 | pubmed:pagination | 427-35 | lld:pubmed |
| pubmed-article:1930940 | pubmed:dateRevised | 2005-11-16 | lld:pubmed |
| pubmed-article:1930940 | pubmed:meshHeading | pubmed-meshheading:1930940-... | lld:pubmed |
| pubmed-article:1930940 | pubmed:meshHeading | pubmed-meshheading:1930940-... | lld:pubmed |
| pubmed-article:1930940 | pubmed:meshHeading | pubmed-meshheading:1930940-... | lld:pubmed |
| pubmed-article:1930940 | pubmed:meshHeading | pubmed-meshheading:1930940-... | lld:pubmed |
| pubmed-article:1930940 | pubmed:meshHeading | pubmed-meshheading:1930940-... | lld:pubmed |
| pubmed-article:1930940 | pubmed:meshHeading | pubmed-meshheading:1930940-... | lld:pubmed |
| pubmed-article:1930940 | pubmed:meshHeading | pubmed-meshheading:1930940-... | lld:pubmed |
| pubmed-article:1930940 | pubmed:meshHeading | pubmed-meshheading:1930940-... | lld:pubmed |
| pubmed-article:1930940 | pubmed:meshHeading | pubmed-meshheading:1930940-... | lld:pubmed |
| pubmed-article:1930940 | pubmed:meshHeading | pubmed-meshheading:1930940-... | lld:pubmed |
| pubmed-article:1930940 | pubmed:meshHeading | pubmed-meshheading:1930940-... | lld:pubmed |
| pubmed-article:1930940 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1930940 | pubmed:articleTitle | The role of genetic predisposition to type I (insulin-dependent) diabetes mellitus. | lld:pubmed |
| pubmed-article:1930940 | pubmed:affiliation | Unité Endocrinologie et Diabète de l'Enfant, Hôpital des Enfants-Malades, Paris, France. | lld:pubmed |
| pubmed-article:1930940 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1930940 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1930940 | lld:pubmed |
